Syntara Limited (@syntaratx) 's Twitter Profile
Syntara Limited

@syntaratx

Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases linked to fibrosis and inflammation.

ID: 66560841

linkhttps://syntaratx.com.au/ calendar_today18-08-2009 01:51:28

453 Tweet

450 Takipçi

231 Takip Edilen

Syntara Limited (@syntaratx) 's Twitter Profile Photo
Syntara Limited
@syntaratx

3 months ago

We've reported further positive interim results from our ongoing Phase 2 trial of SNT-5505 in combination with ruxolitinib for the treatment of myelofibrosis. 73% of evaluable patients achieved a ≥50% reduction in total symptom score and 44% achieved a ≥25% spleen volume

We've reported further positive interim results from our ongoing Phase 2 trial of SNT-5505 in combination with ruxolitinib for the treatment of myelofibrosis. 73% of evaluable patients achieved a ≥50% reduction in total symptom score and 44% achieved a ≥25% spleen volume